Humanwell Healthcare Group Co Ltd

600079.CG▼2

Hubei's former richest man Ai Luming criminally detained on suspicion of illegally absorbing public deposits

Ai Luming, the former richest man in Hubei and former head of Dangdai Group, was criminally detained by the Wuhan Public Security Bureau on July 8, 2026, on suspicion of illegally absorbing public deposits. His defense lawyer, Lan He, said that two meeting requests since July 23 have been blocked. Ai Luming started his career by collecting urine from public toilets to extract urokinase, gradually building a hundred-billion-level Dangdai conglomerate spanning pharmaceuticals, finance, and real estate. At its peak, it held stakes in multiple listed companies such as Humanwell Healthcare and Tianfeng Securities. In 2021, Dangdai Group's debt crisis erupted, and in 2024 it entered bankruptcy restructuring with liabilities as high as 80.6 billion yuan. A subsidiary of China Merchants Group participated in the restructuring with 11.8 billion yuan, and control of Humanwell Healthcare has changed hands. Regulatory investigations show that Dangdai Group accumulated non-operational occupation of 12.785 billion yuan of Humanwell Healthcare's funds and over 4 billion yuan of Sante Cableways' funds, while Tianfeng Securities illegally provided over 8.5 billion yuan in financing for Dangdai Group. Ai Luming was successively fined over 10 million yuan and banned from the securities market for life. This criminal detention mainly targets the comprehensive default of targeted financing products issued by Changzhongsuo under the Dangdai conglomerate, with the suspected illegally absorbed public deposits amounting to approximately 4.8 billion yuan, and the flow of funds still to be investigated.

600079.CG ▼601162.CG ▼002159.CS ▼

时代周报·16dRead more ▾

600079.CG▲

ST Renfu's Sufentanil Citrate Injection Approved for Labor Analgesia Clinical Trial

ST Renfu announced that its controlled subsidiary Yichang Renfu recently received a Drug Clinical Trial Approval Notice for Sufentanil Citrate Injection issued by the National Medical Products Administration, agreeing to conduct a clinical trial of the drug as an analgesic combined with bupivacaine for epidural administration in labor analgesia. Sufentanil is a potent opioid analgesic. Yichang Renfu's product was approved for marketing in 2005 and passed consistency evaluation in 2020. The originally approved indications are for combined anesthesia in general anesthesia and for anesthesia induction and maintenance. This application is for adding a new indication.

600079.CG ▲

Jiemian·16dRead more ▾

600079.CG▲

ST Renfu Subsidiary Yichang Humanwell Receives Drug Registration Certificate for Brexpiprazole Tablets

ST Renfu announced that its holding subsidiary Yichang Humanwell Pharmaceutical recently received the drug registration certificate for Brexpiprazole Tablets approved by the National Medical Products Administration. The specifications include 0.5 mg, 1 mg, and 2 mg, with a registration classification of chemical drug category 4, and the approval number is valid until July 27, 2031. The drug is mainly used for the treatment of schizophrenia in adults. The original product was developed by Otsuka Pharmaceutical and was approved for marketing in China in 2024.

600079.CG ▲

Jiemian·21dRead more ▾

600079.CG▲

Six stocks register for dividends today; Foxconn Industrial Internet leads with 6.50 yuan per 10 shares

Based on the equity registration date, a total of six listed companies will implement their dividend plans today. Among them, four companies are distributing at least 1 yuan in cash per 10 shares. Foxconn Industrial Internet offers the most generous payout at 6.50 yuan per 10 shares, followed by Spring Airlines and ST Humanwell with 5.30 yuan and 4.80 yuan per 10 shares respectively. Looking at share price performance over the past five trading days, Guomai Culture rose 5.05 percent, the biggest gainer, while Visual China Group and ST Humanwell climbed 2.95 percent and 2.63 percent respectively. In contrast, Foxconn Industrial Internet fell 14.44 percent over the same period. Statistics show that a total of 3,651 A-share companies have proposed distribution plans for 2025, of which 3,640 include cash dividends, with total cash payouts reaching 1.59 trillion yuan.

000681.CS ▲301052.CS ▲600079.CG ▲601021.CG ▲601138.CG ▲

证券时报·27dRead more ▾

600079.CG▲

ST Renfu Subsidiary Obtains Drug Registration Certificate for Carbamazepine Extended-Release Tablets (II)

ST Renfu announced that its controlling subsidiary, Yichang Renfu, has received the Drug Registration Certificate for Carbamazepine Extended-Release Tablets (II) from the National Medical Products Administration, with specifications of 100 mg, 200 mg, and 400 mg, approved as a Category 3 chemical drug. The drug is primarily used to treat epilepsy and relieve trigeminal neuralgia. It was developed under dual filing standards for China and the United States and co-line production, and had already received an ANDA approval from the U.S. FDA in January 2025.

600079.CG ▲

Jiemian·31dRead more ▾

600079.CG▲

ST Renfu's HW211026 Ointment Enters Phase II Clinical Trial

ST Renfu announced that its wholly-owned subsidiary, Research Institute Co., Ltd., has independently developed the chemical drug Class 1 innovative drug HW211026 ointment, which has entered Phase II clinical trials. The study is a multicenter, open-label, dose-finding Phase II clinical trial designed to evaluate its efficacy in treating actinic keratosis. HW211026 ointment received clinical trial approval in October 2024. Currently, no drugs with the same target and indication are available on the domestic market, and existing non-drug treatments have issues such as high cost, invasiveness, and poor patient compliance.

600079.CG ▲

Jiemian·49dRead more ▾

600079.CG▲

ST Renfu Subsidiary Receives Clinical Trial Approval for Hydromorphone Hydrochloride Tablets

ST Renfu announced that its controlling subsidiary, Yichang Renfu, recently received a Drug Clinical Trial Approval Notice for Hydromorphone Hydrochloride Tablets from the National Medical Products Administration, granting permission to conduct a randomized controlled clinical study for the treatment of moderate to severe postoperative pain in adults. The drug is a Class 3 chemical drug and has not yet been approved for marketing in China. To date, Yichang Renfu has invested approximately 5.4 million yuan in the project. The company stated that it must complete clinical studies before applying for production and marketing, and the research and approval process involves long cycles and multiple steps with uncertainties, reminding investors to be aware of the risks.

600079.CG ▲

Jiemian·52dRead more ▾